ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel)
ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel) as first-line consolidation therapy for large B-cell lymphoma